1
|
Zhao Z, Patel PA, Slatnick L, Sitthi-Amorn A, Bielamowicz KJ, Nunez FA, Walsh AM, Hess J, Rossoff J, Elgarten C, Myers R, Saab R, Basbous M, Mccormick M, Aftandilian C, Richards R, Nessle CN, Tribble AC, Sheth Bhutada JK, Coven SL, Runco D, Wilkes J, Gurunathan A, Guinipero T, Belsky JA, Lee K, Wong V, Malhotra M, Armstrong A, Jerkins LP, Cross SJ, Fisher L, Stein MT, Wu NL, Yi T, Orgel E, Haeusler GM, Wolf J, Demedis JM, Miller TP, Esbenshade AJ. Prospective External Validation of the Esbenshade Vanderbilt Models Accurately Predicts Bloodstream Infection Risk in Febrile Non-Neutropenic Children With Cancer. J Clin Oncol 2024; 42:832-841. [PMID: 38060973 PMCID: PMC10906655 DOI: 10.1200/jco.23.01814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 09/11/2023] [Accepted: 10/17/2023] [Indexed: 02/29/2024] Open
Abstract
PURPOSE The optimal management of fever without severe neutropenia (absolute neutrophil count [ANC] ≥500/µL) in pediatric patients with cancer is undefined. The previously proposed Esbenshade Vanderbilt (EsVan) models accurately predict bacterial bloodstream infections (BSIs) in this population and provide risk stratification to aid management, but have lacked prospective external validation. MATERIALS AND METHODS Episodes of fever with a central venous catheter and ANC ≥500/µL occurring in pediatric patients with cancer were prospectively collected from 18 academic medical centers. Variables included in the EsVan models and 7-day clinical outcomes were collected. Five versions of the EsVan models were applied to the data with calculation of C-statistics for both overall BSI rate and high-risk organism BSI (gram-negative and Staphylococcus aureus BSI), as well as model calibration. RESULTS In 2,565 evaluable episodes, the BSI rate was 4.7% (N = 120). Complications for the whole cohort were rare, with 1.1% (N = 27) needing intensive care unit (ICU) care by 7 days, and the all-cause mortality rate was 0.2% (N = 5), with only one potential infection-related death. C-statistics ranged from 0.775 to 0.789 for predicting overall BSI, with improved accuracy in predicting high-risk organism BSI (C-statistic 0.800-0.819). Initial empiric antibiotics were withheld in 14.9% of episodes, with no deaths or ICU admissions attributable to not receiving empiric antibiotics. CONCLUSION The EsVan models, especially EsVan2b, perform very well prospectively across multiple academic medical centers and accurately stratify risk of BSI in episodes of non-neutropenic fever in pediatric patients with cancer. Implementation of routine screening with risk-stratified management for non-neutropenic fever in pediatric patients with cancer could safely reduce unnecessary antibiotic use.
Collapse
Affiliation(s)
- Zhiguo Zhao
- Department of Biostatistics, Vanderbilt University Medical Center and the Vanderbilt-Ingram Cancer Center, Nashville, TN
| | - Pratik A. Patel
- Pediatric Hematology/Oncology, Emory University School of Medicine and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
| | - Leonora Slatnick
- Department of Pediatrics, Section of Pediatric Hematology/Oncology, University of Colorado Anschutz Medical Center, Children's Hospital Colorado, Aurora, CO
| | - Anna Sitthi-Amorn
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
| | - Kevin J. Bielamowicz
- University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR
| | - Farranaz A. Nunez
- University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR
| | | | | | - Jenna Rossoff
- Department of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Caitlin Elgarten
- Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA
| | - Regina Myers
- Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA
| | - Raya Saab
- Children's Cancer Institute, Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon
| | - Maya Basbous
- Children's Cancer Institute, Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon
| | | | - Catherine Aftandilian
- Department of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine Stanford University, Palo Alto, CA
| | - Rebecca Richards
- Department of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine Stanford University, Palo Alto, CA
| | - C. Nathan Nessle
- Department of Pediatrics, Division of Pediatric Hematology Oncology, University of Michigan, Ann Arbor, MI
| | - Alison C. Tribble
- Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Michigan, Ann Arbor, MI
| | - Jessica K. Sheth Bhutada
- Cancer and Blood Disease Institute, Children's Hospital of Los Angeles, Los Angeles, CA
- Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Scott L. Coven
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN
| | - Daniel Runco
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN
| | - Jennifer Wilkes
- Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA
| | - Arun Gurunathan
- Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA
| | - Terri Guinipero
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Nationwide Children's Hospital, Columbus, OH
| | - Jennifer A. Belsky
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Division of Pediatric Hematology/Oncology, Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis, IN
| | - Karen Lee
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA
| | - Victor Wong
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Rady Children's Hospital San Diego, University of California San Diego, San Diego, CA
| | - Megha Malhotra
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Washington University in St Louis School of Medicine, St Louis, MO
| | - Amy Armstrong
- Department of Pediatrics, Division of Pediatric Hematology and Oncology, Washington University in St Louis School of Medicine, St Louis, MO
| | - Lauren P. Jerkins
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
| | - Shane J. Cross
- Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN
| | - Lyndsay Fisher
- University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, AR
| | - Madison T. Stein
- Children's Hospital of Philadelphia, Division of Oncology, Philadelphia, PA
| | - Natalie L. Wu
- Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA
| | - Troy Yi
- Division of Pediatric Hematology and Oncology and Bone Marrow Transplant, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA
| | - Etan Orgel
- Cancer and Blood Disease Institute, Children's Hospital of Los Angeles, Los Angeles, CA
- Keck School of Medicine, University of Southern California, Los Angeles, CA
| | | | - Joshua Wolf
- Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN
| | - Jenna M. Demedis
- Department of Pediatrics, Section of Pediatric Hematology/Oncology, University of Colorado Anschutz Medical Center, Children's Hospital Colorado, Aurora, CO
| | - Tamara P. Miller
- Pediatric Hematology/Oncology, Emory University School of Medicine and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA
| | - Adam J. Esbenshade
- Department of Pediatrics, Vanderbilt University Medical Center and the Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt-Ingram Cancer Center, Nashville, TN
| |
Collapse
|
2
|
Prather CS, Wood JB, Mueller EL, Christenson JC, Alali M. The Yield, Safety, and Cost-effectiveness of Decreasing Repeat Blood Cultures Beyond 48 Hours in a Pediatric Hematology-Oncology Unit. J Pediatr Hematol Oncol 2023; 45:409-415. [PMID: 37526364 DOI: 10.1097/mph.0000000000002711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/18/2022] [Accepted: 06/13/2023] [Indexed: 08/02/2023]
Abstract
Clear recommendations are needed on when repeat blood cultures (BCxs) in hospitalized children with cancer should be obtained. We reviewed all BCx obtained on the Hematology-Oncology Unit at Riley Hospital for Children, regardless of reason for patient admission or neutropenia status, between January 2015 and February 2021. Patients with positive BCx within 48 hours of initial cultures, history of stem cell transplant, or admitted to the intensive care unit were excluded. Medical records of patients with new positive BCx drawn >48 hours after initial BCx were reviewed. Seven (1.2%) hospitalization episodes grew new pathogens, or commensals treated as pathogens, on cultures beyond 48 hours. All patients with new, true pathogens were hemodynamically unstable or had recurrent fever when the new positive BCx was obtained. Twenty-three (4.0%) hospitalization episodes had contaminant cultures beyond 48 hours, with 74 (5.4%) of 1362 BCx collected beyond 48 hours being contaminated, resulting in an additional cost of $210,519 from increased length of stay. In conclusion, repeat BCx beyond 48 hours in pediatric hematology-oncology patients with negative initial cultures are low yield and costly. Repeat BCx can be safely and cost-effectively ceased after 48 hours of negative cultures in hemodynamically and clinically stable patients.
Collapse
Affiliation(s)
| | - James B Wood
- Ryan White Center for Pediatric Infectious Diseases and Global Health
- Center for Pediatric and Adolescent Comparative Effectiveness Research
| | - Emily L Mueller
- Center for Pediatric and Adolescent Comparative Effectiveness Research
- Section of Pediatric Hematology-Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN
| | | | - Muayad Alali
- Ryan White Center for Pediatric Infectious Diseases and Global Health
| |
Collapse
|
4
|
Wang J, Tao Z, Zhang K, Wang S. Infection Control-Based Construction of a Fever Outpatient Routine Management Model. Emerg Med Int 2022; 2022:2902800. [PMID: 36158767 PMCID: PMC9492434 DOI: 10.1155/2022/2902800] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 08/16/2022] [Indexed: 11/17/2022] Open
Abstract
Purpose Outbreaks caused by infectious diseases are now serious public health events. At present, most hospitals have a high number of fever clinic attendances. In order to improve the efficiency of fever clinic screening, timely detection and control of infection sources, early detection, early isolation, and early treatment, our hospital explored the construction and effect of our fever clinic management model during the response period by constructing a fever clinic regular management model based on the principles of infection control. Methods 1300 cases (September 2021 to February 2022) with or without epidemiological history were divided into the control group (without epidemiological history) and the observation group (with epidemiological history) and patients were given differentiated management. A model of permanent management of a fever clinic during the epidemic was set up and evaluated by implementing the person responsible for epidemic positions, optimizing tertiary care, and strengthening nosocomial infection protection for health care workers. Results The results showed that patients in the observation group had a lower age of onset, a longer consultation time, and a higher proportion of patients with fever, which was different from the control group (P < 0.05). Compared with the control group, the proportion of routine blood tests, the proportion of four respiratory virus tests, and the per capita cost were higher in the observation group, and the differences were statistically significant (P < 0.05). There were no missed diagnoses, underreporting, cross-infections, or nosocomial infections in either group, and there were no significant differences between the two groups in terms of patients' evaluation of management quality and satisfaction with management (P > 0.05). The skill level, management attitude, and standardized operation of outpatient clinic managers improved after the construction of a fever clinic standing management model based on infection control, and the recognition of patients was higher in the observation group (P < 0.05). Conclusion The construction of a fever outpatient routine management model based on the principle of infection control is conducive to the standardized implementation of the management and treatment of health care workers, early detection of the source of transmission to cut off the transmission route, avoiding cross-infection and nosocomial infection, and ensuring the safety of patients and health care workers.
Collapse
Affiliation(s)
- Jingsong Wang
- Department of Fever Clinic, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
| | - Zhen Tao
- Department of Infectious Disease, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
| | - Kai Zhang
- Department of Fever Clinic, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
| | - Shuai Wang
- Department of Operating Theatre, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu Province, China
| |
Collapse
|